Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time
00

FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time

Nov 20, 2026

The FDA rejected Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy for a second time on November 20, 2026, citing data-integrity violations including unauthorized statistical analysis changes and blinding breaches. An FDA advisory panel had voted 9-3 against the drug in July 2026. Capricor shares fell more than 80% in afterhours trading; CEO Linda Marban said deep staff cuts are coming.

FDA rejection of deramiocel

  • ▪The FDA rejected Capricor Therapeutics' deramiocel therapy for Duchenne muscular dystrophy on November 20, 2026, determining the evidence did not meet the standard for approval
  • ▪Capricor's original deramiocel approval application was denied in July 2025 after the FDA found it lacked substantial evidence of effectiveness
  • ▪Capricor resubmitted the deramiocel application after new data from a late-stage study found the drug met its primary and secondary endpoints, showing improved upper limb and cardiac function
  • ▪An FDA advisory panel voted 9-3 against deramiocel in July 2026, finding the available evidence did not support the drug's effectiveness
  • ▪The November 20, 2026 FDA rejection of deramiocel was the second time the agency had rejected the therapy

Clinical trial data violations

  • ▪A group of 28 physicians and researchers involved in deramiocel development sent a letter to senior FDA leadership in October 2026 advocating for the drug's approval
  • ▪The plan for how results from deramiocel's late-stage clinical trial would be analyzed changed after the trial had already begun, triggering criticism from FDA staff
  • ▪The FDA cited serious data-integrity violations in the deramiocel clinical trial, including unauthorized changes to statistical analyses and breaches of blinding procedures
  • ▪The FDA determined the data-integrity problems in a key clinical trial for deramiocel were so severe that the data could not be considered reliable or corrected after the fact

Capricor financial fallout

  • ▪Capricor Therapeutics shares fell more than 80% in afterhours trading in New York following the November 20, 2026 FDA rejection of deramiocel
  • ▪Capricor Therapeutics CEO Linda Marban said the company would need to make deep cuts to its team following the FDA's rejection of deramiocel
  • ▪Capricor Therapeutics shares had dropped more than 73% year to date as of November 20, 2026
  • ▪Capricor Therapeutics laid off 10% of its staff in early November 2026 ahead of the FDA's decision on deramiocel

Rare disease treatment debate

  • ▪Capricor CEO Linda Marban expressed shock at the FDA's rejection of deramiocel, stating the company did not anticipate the decision
  • ▪The FDA's handling of deramiocel was being closely watched by doctors, patients, and industry leaders amid policy changes and a leadership vacuum at the agency
  • ▪Capricor CEO Linda Marban said Capricor requested 13 meetings with the FDA from April through October 2026 and the FDA denied each of them

Duchenne muscular dystrophy background

  • ▪Deramiocel was designed to protect muscle tissue that Duchenne muscular dystrophy progressively destroys, distinguishing it from other approved drugs that slow the condition or address its genetic mutations
  • ▪Approximately 15,000 Americans have Duchenne muscular dystrophy, and the condition affects almost entirely boys
  • ▪Duchenne muscular dystrophy is a genetic condition in which the body does not produce the dystrophin protein essential for muscle function

4 sources

Reuters
Capricor's Duchenne treatment fails to get FDA approval, shares sink | Reuters
View source article
STAT News
FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time coming
View source article
Endpoints
Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial
View source article
Bloomberg
Capricor Drops After FDA Again Rejects Muscular Dystrophy Drug
View source article

Story comments

Loading comments…

Related entities

New YorkUnited States

Topics

Genetic diseasesStock market performanceFDA drug approvalClinical trial transparencyRare diseasesDrug Policy, Pricing & ApprovalCorporate layoffsClinical trial design